Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study

Open access
Chow, Clara K, Ramasundarahettige, Chinthanie, Hu, Weihong, AlHabib, Khalid F, Avezum, Alvaro, Cheng, Xiaoru, Chifamba, Jephat, Dagenais, Gilles, Dans, Antonio, Egbujie, Bonaventure A, Gupta, Rajeev, Iqbal, Romaina, Ismail, Noorhassim, Keskinler, Mirac V, Khatib, Rasha, Kruger, Lanthé, Kumar, Rajesh, Lanas, Fernando, Lear, Scott, Lopez-Jaramillo, Patricio, McKee, Martin, Mohammadifard, Noushin, Mohan, Viswanathan, Mony, Prem, Orlandini, Andres, Rosengren, Annika, Vijayakumar, Krishnapillai, Wei, Li, Yeates, Karen, Yusoff, Khalid, Yusuf, Rita, Yusufali, Afzalhussein, Zatonska, Katarzyna, Zhou, Yihong, Islam, Shariful, Corsi, Daniel, Rangarajan, Sumathy, Teo, Koon, Gerstein, Hertzel C, Yusuf, Salim · 2018 · The Lancet Diabetes & Endocrinology

Abstract

BACKGROUND Data are scarce on the availability and affordability of essential medicines for diabetes. Our aim was to examine the availability and affordability of metformin, sulfonylureas, and insulin across multiple regions of the world and explore the effect of these on medicine use. METHODS In the Prospective Urban Rural Epidemiology (PURE) study, participants aged 35-70 years (n=156 625) were recruited from 110 803 households, in 604 communities and 22 countries; availability (presence of any dose of medication in the pharmacy on the day of audit) and medicine cost data were collected from pharmacies with the Environmental Profile of a Community's Health audit tool. Our primary analysis was to describe the availability and affordability of metformin and insulin and also commonly used and prescribed combinations of two medicines for diabetes management (two oral drugs, metformin plus a sulphonylurea [either glibenclamide (also known as glyburide) or gliclazide] and one oral drug plus insulin [metformin plus insulin]). Medicines were defined as affordable if the cost of medicines was less than 20% of capacity-to-pay (the household income minus food expenditure). Our analyses included data collected in pharmacies and data from representative samples of households. Data on availability were ascertained during the pharmacy audit, as were data on cost of medications. These cost data were used to estimate the cost of a month's supply of essential medicines for diabetes. We estimated affordability of medicines using income data from household surveys. FINDINGS Metformin was available in 113 (100%) of 113 pharmacies from high-income countries, 112 (88·2%) of 127 pharmacies in upper-middle-income countries, 179 (86·1%) of 208 pharmacies in lower-middle-income countries, 44 (64·7%) of 68 pharmacies in low-income countries (excluding India), and 88 (100%) of 88 pharmacies in India. Insulin was available in 106 (93·8%) pharmacies in high-income countries, 51 (40·2%) pharmacies in upper-middle-income countries, 61 (29·3%) pharmacies in lower-middle-income countries, seven (10·3%) pharmacies in lower-income countries, and 67 (76·1%) of 88 pharmacies in India. We estimated 0·7% of households in high-income countries and 26·9% of households in low-income countries could not afford metformin and 2·8% of households in high-income countries and 63·0% of households in low-income countries could not afford insulin. Among the 13 569 (8·6% of PURE participants) that reported a diagnosis of diabetes, 1222 (74·0%) participants reported diabetes medicine use in high-income countries compared with 143 (29·6%) participants in low-income countries. In multilevel models, availability and affordability were significantly associated with use of diabetes medicines. INTERPRETATION Availability and affordability of essential diabetes medicines are poor in low-income and middle-income countries. Awareness of these global differences might importantly drive change in access for patients with diabetes. FUNDING Full funding sources listed at the end of the paper (see Acknowledgments).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(18)30233-x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 203

Metadata

Authors
Chow, C. K., Ramasundarahettige, C., Hu, W., AlHabib, K. F., Avezum, A., Cheng, X., Chifamba, J., Dagenais, G., Dans, A., Egbujie, B. A., Gupta, R., Iqbal, R., Ismail, N., Keskinler, M. V., Khatib, R., Kruger, L., Kumar, R., Lanas, F., Lear, S., Lopez-Jaramillo, P., McKee, M., Mohammadifard, N., Mohan, V., Mony, P., Orlandini, A., Rosengren, A., Vijayakumar, K., Wei, L., Yeates, K., Yusoff, K., Yusuf, R., Yusufali, A., Zatonska, K., Zhou, Y., Islam, S., Corsi, D., Rangarajan, S., Teo, K., Gerstein, H. C., & Yusuf, S.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2018-10
Volume
6
Issue
10
Pages
798-808
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2889089805
Cited by
203
References
3
FWCI
27.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. https://app.cochat.ai/papers/10.1016/s2213-8587(18)30233-x
The paper
Chow, C. K., Ramasundarahettige, C., Hu, W., AlHabib, K. F., Avezum, A., Cheng, X., Chifamba, J., Dagenais, G., Dans, A., Egbujie, B. A., Gupta, R., Iqbal, R., Ismail, N., Keskinler, M. V., Khatib, R., Kruger, L., Kumar, R., Lanas, F., Lear, S., . . . Yusuf, S. (2018). Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30233-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.